Advanced search
Add to list

CD20-Tcb (RG6026), a novel '' 2:1 '' format T-cell-engaging bispecific antibody, induces complete remissions in relapsed/refractory B-cell non-Hodgkin's lymphoma : preliminary results from a phase I first in human trial

(2018) BLOOD. 132(suppl. 1).
Author
Organization

Citation

Please use this url to cite or link to this publication:

MLA
Hutchings, Martin et al. “CD20-Tcb (RG6026), a Novel ‘ 2:1 ’ Format T-cell-engaging Bispecific Antibody, Induces Complete Remissions in Relapsed/refractory B-cell non-Hodgkin’s Lymphoma : Preliminary Results from a Phase I First in Human Trial.” Blood. Vol. 132. 2018. Print.
APA
Hutchings, M., Iacoboni, G., Morschhauser, F., Offner, F., Sureda, A., Salles, G. A., Carlo-Stella, C., et al. (2018). CD20-Tcb (RG6026), a novel “ 2:1 ” format T-cell-engaging bispecific antibody, induces complete remissions in relapsed/refractory B-cell non-Hodgkin’s lymphoma : preliminary results from a phase I first in human trial. BLOOD (Vol. 132). Presented at the 60th Annual meeting of the American Society of Hematology (ASH).
Chicago author-date
Hutchings, Martin, Gloria Iacoboni, Franck Morschhauser, Fritz Offner, Anna Sureda, Gilles Andre Salles, Carmelo Carlo-Stella, et al. 2018. “CD20-Tcb (RG6026), a Novel ‘ 2:1 ’ Format T-cell-engaging Bispecific Antibody, Induces Complete Remissions in Relapsed/refractory B-cell non-Hodgkin’s Lymphoma : Preliminary Results from a Phase I First in Human Trial.” In Blood. Vol. 132.
Chicago author-date (all authors)
Hutchings, Martin, Gloria Iacoboni, Franck Morschhauser, Fritz Offner, Anna Sureda, Gilles Andre Salles, Carmelo Carlo-Stella, Joaquin Martinez Lopez, Denise Thomas, Peter N Morcos, Betsy Quackenbush, Cristiano Ferlini, Marina Bacac, Ann-Marie E Broeske, Natalie Dimier, Tom Moore, Martin Weisser, and Michael Dickinson. 2018. “CD20-Tcb (RG6026), a Novel ‘ 2:1 ’ Format T-cell-engaging Bispecific Antibody, Induces Complete Remissions in Relapsed/refractory B-cell non-Hodgkin’s Lymphoma : Preliminary Results from a Phase I First in Human Trial.” In Blood. Vol. 132.
Vancouver
1.
Hutchings M, Iacoboni G, Morschhauser F, Offner F, Sureda A, Salles GA, et al. CD20-Tcb (RG6026), a novel “ 2:1 ” format T-cell-engaging bispecific antibody, induces complete remissions in relapsed/refractory B-cell non-Hodgkin’s lymphoma : preliminary results from a phase I first in human trial. BLOOD. 2018.
IEEE
[1]
M. Hutchings et al., “CD20-Tcb (RG6026), a novel " 2:1 " format T-cell-engaging bispecific antibody, induces complete remissions in relapsed/refractory B-cell non-Hodgkin’s lymphoma : preliminary results from a phase I first in human trial,” in BLOOD, San Diego, CA, USA, 2018, vol. 132, no. suppl. 1.
@inproceedings{8618783,
  articleno    = {abstract 226},
  author       = {Hutchings, Martin and Iacoboni, Gloria and Morschhauser, Franck and Offner, Fritz and Sureda, Anna and Salles, Gilles Andre and Carlo-Stella, Carmelo and Martinez Lopez, Joaquin and Thomas, Denise and Morcos, Peter N and Quackenbush, Betsy and Ferlini, Cristiano and Bacac, Marina and Broeske, Ann-Marie E and Dimier, Natalie and Moore, Tom and Weisser, Martin and Dickinson, Michael},
  booktitle    = {BLOOD},
  issn         = {0006-4971},
  language     = {eng},
  location     = {San Diego, CA, USA},
  number       = {suppl. 1},
  title        = {CD20-Tcb (RG6026), a novel '' 2:1 '' format T-cell-engaging bispecific antibody, induces complete remissions in relapsed/refractory B-cell non-Hodgkin's lymphoma : preliminary results from a phase I first in human trial},
  url          = {http://dx.doi.org/10.1182/blood-2018-99-110207},
  volume       = {132},
  year         = {2018},
}

Altmetric
View in Altmetric
Web of Science
Times cited: